ABN 16 165 160 841

ASX RELEASE **21st October 2020**

Amplia Presents at Reach Market Services "Meet the CEO"

Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to provide the CEO's Presentation which will be made today at 12 p.m. AEDT via a live webinar hosted by Reach Markets.

To participate, please register at: www.reachmarkets.com.au/meet-the-ceos

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information
Dr. John Lambert
CEO and Managing Director
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Amplia Therapeutics

October 2020

Amplia Therapeutics Limited

Amplia
Exposing cancer. Enhancing treatment.

Disclaimer

The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited ("Amplia") in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation contains forward-looking statements which can be identified by the use of words such as "may", "should", "will", "expect", "anticipate", "believe", "estimate", "intend", "scheduled" or "continue" or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Amplia, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Amplia's acquired product pipeline. Actual results from clinical trials may vary from those shown.

Company highlights

Developing small molecule drugs for two, significant disease areas:

- **cancer** – combo therapy in hard-to-treat solid tumours
- **fibrosis** – prevention and treatment

Range of commercial opportunities for partnering, licensing and co-development

First Phase 1 clinical trial started in October 2020

Data from Phase 1 will be relevant for multiple cancer and fibrotic disease indications

Investigational New Drug (IND) designation and Phase 2 clinical trial program targeted in 2021

Amplia's FAKi's provide a promising opportunity set

Amplia is developing Amplia's experimental drug candidates offer several commercial opportunities

Amplia is taking three approaches to realize these opportunities:

1. **Clinical development** for pancreatic cancer and idiopathic lung fibrosis (both granted Orphan Drug Designations by the FDA)

2. **license, partner or co-develop** other applications including other cancer combination therapies, fibrotic diseases, uveal melanoma



Company snapshot[1]

Shares	107.4M
Market cap	$29.0M
Options	14.1M
Cash [2]	$4.0M
Last qtr burn [3]	($0.4M)
Listed	May 2018
Headquarters	Melbourne
Board	Warwick Tong (Chair) John Lambert (MD) Robert Peach (NED) Chris Burns (NED)
Substantial institutional holders	Platinum – 16.2% Blueflag Holdings – 7.1%

[1] as at 19 Oct 2020
[2] cash held at 31 Aug 2020
[3] quarter ending 30 Jun 2020

ATX Price and Volume – 12 months

price	$0.27
12mth high - low	$0.27 - $0.05
av. daily volume	255,000

Achievements to date in 2020

- **Jan 2020** – Placement raising $930K at $0.07/share corner-stoned by Platinum
- **Jan 2020** – Completed restructure and streamlining of Board
- **Feb 2020** – Paul Timpson joins Scientific Advisory Board
- **Mar 2020** – Orphan Drug Designation awarded for pancreatic cancer
- **May 2020** – Orphan Drug Designation awarded for idiopathic pulmonary fibrosis
- **Jun 2020** – Completed toxicology studies required to support Phase 1 clinical trial
- **Jul 2020** – Rights Issue raising $4.0M at $0.10/share
- **Aug 2020** – Mark Devlin appointed as Chief Scientific Officer
- **Sep 2020** – Receives ethics clearance to conduct Phase 1 trial in healthy volunteers
- **Oct 2020** – First volunteers dosed in Phase 1 trial

Cancer Treatments



Amplia
Exposing cancer. Enhancing treatment.

Why cancer drugs often do not work

Pharmaceutical strategies to treat cancer:

1. **cytotoxic drugs**: target rapidly dividing cancer cells
2. **targeted drugs**: block specific proteins elevated in cancer cells
3. **anti-angiogenic drugs**: block new blood vessels which feed the cancer
4. **immuno-oncology (I-O) drugs**: activate the immune system to attack the cancer

The effectiveness of these drugs limited by tumour 'defence' mechanisms which:

- allow cancers to migrate spread to other sites in the body
- generate resistant cancer cells
- physically shield the cancer from the immune system
- dampen the immune system's response against the cancer

Amplia's drugs target cancer defence mechanisms



Focal Adhesion Kinase (FAK)

Fibrosis
FAK helps establish and maintain the dense, fibrotic tissue around cancers
Immune activity
FAK triggers the release of signaling molecules (cytokines) which suppress the immune system
Cell migration
FAK regulates cell migration that is involved in the formation of secondary cancers (metastases)

- elevated levels of FAK in cancers are associated with poor outcomes
- increased FAK activity is found in many difficult-to-treat, solid cancers
- FAK is involved in many cancer defence mechanisms that reduce the effectiveness of cancer drugs
- Amplia is investigating the use of FAK inhibitors (FAKi's) to disrupt cancer defence mechanisms, making them more responsive to cancer drugs

Remove the shield. Deliver the blow.

AMP945 – treatment of solid cancers

Pancreatic cancer

- FDA Orphan Drug Designation for AMP945 in the treatment of pancreatic cancer received in March 2020
- Collaboration with Prof. Paul Timpson at the Garvan Institute to assess novel combination therapies for pancreatic cancer
- These studies will help guide future clinical trials in patients with pancreatic cancer

Other cancers

- Amplia plans to perform nonclinical studies to evaluate combining AMP945 with other cancer drugs
- These studies will inform the structure and design on Amplia's Phase 2 clinical program



Fibrosis Treatments

Amplia
Exposing cancer. Enhancing treatment.

FAK in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a devastating, progressive disease caused by the build-up of fibrotic tissue in the lung which affects 3M people worldwide, including 130,000 in the US

- Left untreated, the median survival time is 2-3 years
- Current drugs increase median life expectancy by 2½ years

FAK has a pivotal role in the biochemical pathways regulating the development and progression of fibrosis in the lungs

Industry standard nonclinical disease model shows that AMP945 both treats and prevents lung fibrosis

- Awarded Orphan Drug Designation by US FDA May 2020

Potential for anti-fibrotic therapy beyond IPF

Microbial respiratory infections

Many bacterial and viral infections damage lung tissue or induce an inflammatory responses that results in scarring and fibrosis which can have long term impacts on respiratory function

Silicosis

Silicosis is an industrial lung disease in which dust particles from sand, rock and minerals containing silica are inhaled and cause extensive scarring in the lungs making it hard to breathe

Non-alcoholic steatohepatitis (NASH)

Scarring of the liver caused by long-term inflammation and the build up of fatty tissues and is the most common chronic liver condition in Western populations (12% prevalence in the US)



Status and Outlook

Amplia
Exposing cancer. Enhancing treatment.

Phase 1 Trial of AMP945

First clinical trial of AMP945 commenced dosing in October 2020

Phase 1 safety trial of orally administered AMP945 in healthy volunteers:

- Single Australian site
- 64 volunteers, cost of ~$2M
- Single ascending dose (SAD) and multiple ascending dose (MAD)
- Forecast 6-9 months to complete

Purpose of the trial:

- Assessment of the clinical safety and absorption of AMP945
- Platform for future clinical studies in cancer and fibrosis patients

Upcoming targeted milestones

- **Nov 2020 –** Significant research collaboration
- **Dec 2020 –** Start dosing of multi-dose arm of Phase 1 clinical trial
- **Q2 2021 -** Selection of first indication for Phase 2 based on preclinical combo studies
- **Q2 2021 -** Headline data from Phase 1 clinical study
- **Q3 2021 -** File Investigational New Drug (IND) Application for AMP945 with FDA
- **Q4 2021 -** Receive IND designation for AMP945
- **H2 2021 -** Initiate Phase 2 program for AMP945 in cancer and IPF

Ampliа

Exposing cancer. Enhancing treatment.

ampliatx.com